CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2004-03-19): Ribavirin's antiviral effect aids interferon in hepatitis C therapy

Clinical

Ribavirin's antiviral effect aids interferon in hepatitis C therapy

Last Updated: 2004-03-19 16:03:37 -0400 (Reuters Health)

NEW YORK (Reuters Health) - In patients with chronic hepatitis C, ribavirin improves the effectiveness of interferon alpha treatment. The mechanism that underlies the combined effect of the two drugs is unclear, however.

In the March issue of Gastroenterology, an international team led by Dr. Jean-Michel Pawlotsky of Hopital Henri Mondor in Paris, France, sheds some light on this mechanism with the results of its analysis of viral kinetics and ribavirin pharmacokinetics in patients with chronic hepatitis C.

Thirty-eight patients received either ribavirin or interferon monotherapy, or interferon and ribavirin in combination. Seven patients served as controls.

Of the 7 patients who received ribavirin alone, 4 had "a significant, moderate, early and transient viral load decrease" at days 2 and 3, according to the researchers. This effect was associated with longer ribavirin clearance half-lives and higher serum concentrations.

In the 8 patients treated with the standard 3-times-per-week interferon injections plus daily ribavirin, the antiviral effect of ribavirin partly reduced the viral load rebound that preceded the second injection. "The magnitude of the rebound was inversely related to ribavirin concentrations," the investigators point out.

After the viral load rebound, patients receiving the standard interferon regimen in combination with ribavirin had "a slow, but significant, second slope of viral decrease and cleared HCV RNA." Patients on ribavirin monotherapy, however, did not experience a second decline in either viral level or HCV RNA clearance.

The authors concede that the mechanisms underlying their observations "remain hypothetical." They conclude that ribavirin's transient antiviral effect "helps explain the better initial and end-of-treatment response when ribavirin is added to interferon alpha."

Gastroenterology 2004;126:703-714.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.